Hansa Biopharma Interim Report January–June 2019
Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome (GBS) continues.Highlights for the second quarter 2019 - At the 2019 American Transplant Congress (ATC), Dr. Edmund Huang of Cedars-Sinai Medical Center presented data demonstrating a significant reduction in time to transplant for highly sensitized patients treated with imlifidase over matched controls waiting under Kidney Allocations System (KAS). Dr. Huang’s session won ATC’s People’s Choice Award for the most impactful presentation. -